Mark Cuban Cost Plus Drug Company Joins Forces With Coherus To Make YUSIMRY, a HUMIRA Biosimilar, Available To Patients
Portfolio Pulse from Benzinga Newsdesk
Mark Cuban Cost Plus Drug Company has partnered with Coherus BioSciences to make YUSIMRY, a HUMIRA biosimilar, available to patients for $569.27 plus dispensing and shipping fees. YUSIMRY will be the first biologic product offered by the company.
June 01, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences partners with Mark Cuban Cost Plus Drug Company to make YUSIMRY, a HUMIRA biosimilar, available to patients, potentially increasing revenue.
The partnership between Coherus BioSciences and Mark Cuban Cost Plus Drug Company to offer YUSIMRY, a HUMIRA biosimilar, has the potential to increase revenue for Coherus. The collaboration will make the product more accessible to patients, which could lead to higher sales and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100